

May 18, 2016

Dear Manufacturers,

I am writing on behalf of The Medical Center Bowling Green ("TMCBG") 340B ID: DSH180013 to inform manufacturers that TMCBG recently underwent an audit by the Health Resources and Services Administration (HRSA) of the Medical Center Bowling Green's compliance with 340B Drug Pricing Program (340 Program) requirements.

As background, The Medical Center Bowling Green qualified for the 340B Program as a disproportionate share hospital in Bowling Green, Kentucky and has participated in the 340B Program since 4/1/2005.

Through the audit process, TMCBG was found to have non-compliance within the 340B Program and is responsible for repayment as a result of the following findings:

*HRSA determined that one (1) outpatient clinic located was ineligible for registration as child site.

*HRSA determined that TMCBG dispensed 340B drugs to ineligible individuals as prohibited by section 340B (a)(5)(B) of the PHSA.

These occurrences are not the result of a program or system failure within TMCBG's 340B operations, but were related to isolated or unique issues.

TMCBG has identified all affected manufacturers and has contacted each to notify them of this violation to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from TMCBG and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter, please contact:

Aric Polston
Corporate Director of Pharmacy
The Medical Center Bowling Green
250 Park Street
Bowling Green, KY 42101
270-745-1640